

CO-FOUNDER NEEDED

Apply to co-found [here](#)
no later than FEB 28, 2025!

Adhesion Score

IVD Cancer Diagnostics – Your body immediately knows about the cancer relapse and so should you

THE PROBLEM

Colorectal cancer is the third most diagnosed cancer; with 1.9 million new cases and over 935.000 deaths yearly. Surgical resection is the primary treatment, but the postoperative recurrence rates are still 30%. Of this 30%, 90% die within 5 years. Timing of detection is crucial. Today Doctors typically discover a relapse through a routine screening program with a typical interval of 3-6 month.

OUR SOLUTION

We are proud to introduce the AdhesionScore™, a novel high-throughput functional cell assay that breaks new ground in predicting a relapse after surgery. By comparing only two standard blood samples the AdhesionScore™ can within only 48 hours provide doctors with a prediction of the patients risk of having a relapse. This prediction enables doctors to plan treatments with unparalleled individual timing and precision. We believe that this will enable an effective differentiation in screening programs allowing doctors to act sooner with higher certainty. Join us to save lives and one day end the scrutinizing doubt of "what if we had known this earlier?".

PATENT STATUS

PCT phase.

FINANCIAL OVERVIEW

CVR expected in Q4 2025. 1 year salary left for Stine Bull in a post doc focused on teaching. Currently fundraising for SPARK and other programs. Burn rate: Current cost covered by RUC. Revenue = 0.

MILESTONES ACHIEVED

- Strong commit to do full-scale implementation and research by Zealand University Hospital – Køge.
- Jan-'25: Advisory Board formed incl. 2 strong Life-science Senior prof. (Dir.) and now active Business angels: Gülizar Skjoldager and Phaedria St. Hilaire. NB. Looking for a IVD specialist atm.
- Patent co-created with the award winning Chief surgent Ismail Gögenur: Chair for Zealand Surgical Forum and Founder of Center for Surgical Science (50+ FTE) at Zealand University Hospital.
- A strong and broad patent covering our testing method on all solid tumor types.

TARGET MARKET & CUSTOMERS

We are still exploring strategies. We wish for a CEO to analyze and decide what GTM strategy to test first. A model in DK could be a small lab (1-2FTE) with a parallel impact study to validate a Health Economics Model with SUH. Market: Larger (US) hospitals have sufficient cell-labs, and a license model looks realistic.

WE ARE LOOKING FOR A HANDS-ON CO-FOUNDER (CEO)

Must-Have Qualifications

Scientific AND business experience is needed. 5+ years in MedTech, proven track record in discovery, due diligence or business development. Be skilled at translating science into strategy, driving execution, and leading diverse teams.

Nice-to-Have background

Scientific from biology, chemistry, medicine, biomedical sciences, etc.

Personal Fit

We imagine an impact driven, entrepreneur with high EQ and a big heart.

TASKS & RESPONSIBILITIES (FIRST 3 MONTHS)

- Conduct due diligence and assess technologies for potential company creation.
- Collaborate with research teams to shape visions and strategies for the new company.
- Build networks of in-house and external talent.
- Lead the development of business roadmaps and stakeholder engagement plans.
- Translate cutting-edge science into commercially viable MedTech programs.

ACADEMIC BACKGROUND OF CURRENT CO-FOUNDERS

Jesper Troelsen: Professor in Molecular and Medical Biology and Group leader (Future Board member). Stine Bull: PostDoc (Future startup CTO/CSO).

ENTREPRENEURIAL ACADEMIC BACKGROUND OF CURRENT CO-FOUNDERS

Jesper: Chairman for spinout for 7 years, Co-inventor of the patent. Stine: 'SpinoutDenmark' and 'School of Health Innovation' Graduate, Co-inventor of the patent.

PHYSICAL ADDRESS

Flexible and currently at Roskilde University.